Manifestations of cutaneous diabetic microangiopathy

American Journal of Clinical Dermatology

Volumn 6, Issue 4, 2005, Pages 225-237

  Ngo, Binh T ^a   Hayes, Kristie D ^a   DiMiao, Dominick J ^a   Srinivasan, Shashi K ^a   Huerter, Christopher J ^b   Rendell, Marc S ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Creighton Diabetes Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C; SORBITOL;

ACANTHOSIS NIGRICANS; BULLOSIS DIABETICORUM; DIABETES MELLITUS; DIABETIC BULLAE; DIABETIC DERMOPATHY; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIABETIC SCLEREDEMA; DISEASE PREDISPOSITION; ERYSIPELAS LIKE ERYTHEMA; HUMAN; ICHTHYOSIS; INFECTION RISK; KYRLE DISEASE; METABOLISM; OPPENHEIM URBACH SYNDROME; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERFUSION; PERIUNGUAL ERYTHEMA; PIGMENTED PURPURAS; PRIORITY JOURNAL; REVIEW; RUBEOSIS FACEI; SKIN BLOOD VESSEL DISORDER; SKIN CAPILLARY; SKIN FUNCTION; SKIN INJURY; SKIN MANIFESTATION; SKIN ULCER; SYMPTOMATOLOGY; THERMAL STIMULATION; THERMOREGULATION;

ALDEHYDE REDUCTASE; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS; PROTEIN KINASE C; REACTIVE OXYGEN SPECIES; SKIN; SKIN DISEASES;

EID: 23844498723     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200506040-00003     Document Type: Review

References (208)

1. Weil AJ. Das verhalten der kleinsten Gefasse beim Diabetes mellitus. Klin Wochenschr 1924; 3: 209
2. Weiss E. Beobachtung und mikrophotographische Darstekllung der Hautkapillaren am lebenden Menschen. Dtsch Arch Klin Med 1916; 119: I, 1916
3. Jurgensen E. Mikrokapillarbeobachtungen und Puls der kleinsten Gefasse. Z Klin Med 1918; 86: 410
4. Aagenaes O, Moe H. Light and electron microscopy study of skin capillaries of diabetics. Diabetes 1961; 10: 253-9
5. Banson BB. Diabetic microangiopathy in human toes. Am J Pathol 1964; 45: 41-58
6. McMillan DE, Breithaupt DL, Rosenau W, et al. Forearm skin capillaries of diabetic, potential diabetic and non-diabetic subjects changes seen by light microscope. Diabetes 1966; 15: 251-7
7. Braverman IM, Keh-Yen A. Ultrastructural abnormalities of the microvasculature and elastic fibers in the skin of juvenile diabetics. J Invest Dermatol 1984; 82: 270-4
8. Braverman IM, Sibley J, Keh-Yen A. A study of the veil cells around normal, diabetic, and aged cutaneous microvessels. J Invest Dermatol 1986; 86: 57-62
9. Grassi W, Gasparini M, Cervini C. Nailfold computed videomicroscopy in morpho-functional assessment of diabetic microangiopathy. Acta Diabetol Lat 1985; 22: 223-8
10. Ditzel J. Functional microangiopathy of DM. Diabetes 1968; 17: 388-97
11. Jorneskog G, Brismar K, Fagrell B. Skin capillary circulation severely impaired in toes of patients with IDDM, with and without late diabetic complications. Diabetologia 1995; 38: 474-80
12. Jorneskog G, Brismar K, Fagrell B. Skin capillary circulation is more impaired in the toes of diabetic than non-diabetic patients with peripheral vascular disease. Diabet Med 1995; 12: 36-44
13. Lawall H, Amann B, Rottmann M, et al. The role of microcirculatory techniques in patients with diabetic foot syndrome. Vasa 2000; 29: 191-7
14. Rendell M, Bergman T, O'Donnell G, et al. Microvascular blood flow, volume, and velocity measured by laser Doppler techniques in insulin dependent diabetes. Diabetes 1989; 38: 819-24
15. Rendell M, Bamisedun O. Diabetic cutaneous microangiopathy. Am J Med 1992; 93: 611-8
16. Mayrovitz HN, Larsen PB. Functional microcirculatory impairment: a possible source of reduced skin oxygen tension in human diabetes mellitus. Microvasc Res 1996; 52: 115-26
17. Aso Y, Inukai T, Takemura Y. Evaluation of microangiopathy of the skin in patients with non-insulin-dependent diabetes mellitus by laser Doppler flowmetry; microvasodilatory responses to beraprost sodium. Diabetes Res Clin Pract 1997; 36: 19-26
18. Bornmyr S, Svensson H, Lilja B, et al. Cutaneous vasomotor responses in young type I diabetic patients. J Diabetes Complications 1997; 11: 21-6
19. Charkoudian N, Vella A, Reed AS, et al. Cutaneous vascular function during acute hyperglycemia in healthy young adults. J Appl Physiol 2002; 93: 1243-50
20. Hoffmann U, Franzeck UK, Bollinger A. Is there a cutaneous microangiopathy in diabetes mellitus? Dtsch Med Wochensch 1994; 119: 36-40
21. Jaap AJ, Pym CA, Seamark C, et al. Microvascular function in type 2 (non-insulin-dependent) diabetes: improved vasodilation after one year of good glycaemic control. Diabet Med 1995; 12: 1086-91
22. Jörneskog G, Brismar K, Fagrell B. Pronounced skin capillary ischemia in the feet of diabetic patients with bad metabolic control. Diabetologia 1998; 41: 410-5
23. Tooke JE. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications 2000; 14: 197-200
24. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 2000; 77: S26-30
25. Laight DW, Carrier MJ, Anggard EE. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev 1999; 15: 274-82
26. Guerci B, Bohme P, Kearney-Schwartz A, et al. Endothelial dysfunction and type 2 diabetes: Part 2. Altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001; 27: 436-47
27. MacGregor LC, Rosecan LR, Laties AM, et al. Altered retinal metabolism in diabetes: I. Microanalysis of lipid, glucose, sorbitol, and myo-inositol in the choroid and in the individual layers of the rabbit retina. J Biol Chem 1986; 261: 4046-51
28. Kador PF. The role of aldose reductase in the development of diabetic complications. Med Res Rev 1988; 8: 325-52
29. Gabbay KH. Hyperglycemia, polyol metabolism, and complications of DM. Annu Rev Med 1975; 26: 521-36
30. Chandra D, Ramana KV, Friedrich B, et al. Role of aldose reductase in TNF-alpha-induced apoptosis of vascular endothelial cells. Chem Biol Interact 2003; 143-144: 605-12
31. Park HK, Ahn CW, Lee GT, et al. (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 151-7
32. Ng DP, Conn J, Chung SS, et al. Aldose reductase (AC)(n) microsatellite polymorphism and diabetic microvascular complications in Caucasian type 1 diabetes mellitus. Diabetes Res Clin Pract 2001; 52: 21-7
33. Okayama N, Omi H, Okouchi M, et al. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules. J Diabetes Complications 2002; 16: 321-6
34. Akamine EH, Hohman TC, Nigro D, et al. Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther 2003; 304: 1236-42
35. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101
36. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-43
37. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-42
38. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49 (2 Suppl. 1): 9-13
39. Aso Y, Inukai T, Tayama K. Serum concentrations of AGEs are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with DM II. Acta Diabetol 2000; 37: 87-92
40. Yamamoto Y, Yamagishi S, Yonekura H, et al. Roles of the AGE-RAGE system in vascular injury in diabetes. Ann N Y Acad Sci 2000; 902: 163-70
41. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-403
42. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 2001; 15: 203-10
43. Kennedy AL, Lyons TJ. Glycation, oxidation, and lipoxidation in the development of diabetic complications. Metabolism 1997; 46 (12 Suppl. 1): 14-21
44. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67
45. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994; 16: 383-91
46. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000; 47: 457-64
47. Stehouwer CD, Lambert J, Donker AJ, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68
48. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25: 255-70
49. Booth G, Stalker TJ, Lefer AM, et al. Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes 2002; 51: 1556-64
50. Nakadate T, Yamamoto S, Aizu E, et al. H-7, a protein kinase C inhibitor, inhibits phorbol ester-caused ornithine decarboxylase induction but fails to inhibit phorbol ester-caused suppression of epidermal growth factor binding in primary cultured mouse epidermal cells. Mol Pharmacol 1989; 36: 917-24
51. Craven PA, De Rubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest 1989; 83: 1667-75
52. Iizuka H, Sakai H, Kinouchi M. Epidermal adenylate cyclase system is regulated by diacylglycerol-protein kinase C signal, but not by calcium signal. Br J Dermatol 1990; 122: 459-67
53. Le Panse R, Mitev V, Lebreton C, et al. Modulation of epidermal growth factor and keratinocyte growth factor effects on human keratinocyte growth by protein kinase C inhibitor, GF 109203X: comparison to fibroblast growth modulation. Biochem Biophys Res Commun 1994; 204: 1081-7
54. Xiong Y, Harmon CS. Interleukin-1beta is differentially expressed by human dermal papilla cells in response to PKC activation and is a potent inhibitor of human hair follicle growth in organ culture. J Interferon Cytokine Res 1997; 17: 151-7
55. Todd C, Reynolds NJ. Up-regulation of p21WAF1 by phorbol ester and calcium in human keratinocytes through a protein kinase C-dependent pathway. Am J Pathol 1998; 153: 39-45
56. Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993; 265 (5 Pt 1): E783-93
57. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-88
58. Ido Y, Chang KC, Lejeune WS, et al. Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation 2001; 8: 251-63
59. Melin H. An atrophic circumscribed skin lesion in the lower extremities of diabetics. Acta Med Scand 1964; 176 Suppl. 423: 1-75
60. Danowski TX, Sabeh G, Sarver ME, et al. Shin spots and diabetes mellitus. Am J Med Sci 1966; 251: 570-5
61. Bauer M, Levan NE. Diabetic dermangiopathy: a spectrum including pretibial pigmented patches and necrobiosis lipoidica diabeticorum. Br J Dermatol 1970; 83: 528-35
62. Lithner F. Cutaneous reactions of the extremities of diabetics to local thermal trauma. Acta Med Scand 1975; 198: 319-25
63. Binkley GW, Giraldo B, Stoughton RB. Diabetic dermopathy: a clinical study. Cutis 1967; 3: 955-8
64. Fisher ER, Danowski TS. Histologic, histochemical, and electron microscopic features of the shin spots of diabetes mellitus. Am J Clin Pathol 1968; 50: 547-54
65. Shemer A, Begman R, Linn S, et al. Diabetic dermopathy and internal complications in diabetes mellitus. Int J Dermatol 1998; 37: 113-5
66. Ohtsuka T. Relationship between periungual erythema and nailfold capillary abnormalities in patients with connective tissue diseases. Eur J Dermatol 1997; 7: 561-5
67. Greene RA, Scher RK. Nail changes associated with diabetes mellitus. J Am Acad Dermatol 1987; 16: 1015-21
68. Landau J, Davis E. The small blood vessels of the conjunctiva and nailbed in diabetes mellitus. Lancet 1960; II: 731-4
69. Yosipovitch G, Hodak E, Vardi P, et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 1998; 21: 506-9
70. Gitelson S, Wertheimer-Kaplinski N. Color of the face in diabetes mellitus: observations on a group of patients in Jerusalem. Diabetes 1965; 14: 201-8
71. Von Noorden C, S Isaac. Die Zuckerkrankheit und ihre Behandlung Ed 8 Berlin, 1927; 279
72. Lundbaek K. Long term diabetes. Ophthalmological section in collaboration with VA Jensen. Copenhage, E. Munksgaard/Lange. London, New York: Maxwell Springer Ltd, 1953
73. Huntley AC. Cutaneous manifestations of diabetes mellitus. Am Acad Dermatol 1982; 7: 427-55
74. Neumann E, Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol 1998; 37: 263-6
75. Lithner F. Purpura, pigmentation and yellow nails of the lower extremities in diabetes. Acta Med Scand 1976; 199: 203-8
76. Kaczander BI. Lower extremity purpura. J Foot Surg 1988; 27: 469-71
77. Kobayashi T, Kawada A, Hiruma M, et al. Prurigo pigmentosa, ketonemia and diabetes mellitus. Dermatology 1996; 192: 78-80
78. Lithner F. Cutaneous erythema, with or without necrosis, localized to the legs and feet: a lesion in elderly diabetics. Acta Med Scand 1974; 196: 33-4
79. Lithner F, Heitala S-O. Skeletal lesions of the feet in diabetics and their relationship to cutaneous erythema with or without necrosis of the feet. Acta Med Scand 1976; 200: 155-61
80. Fitzcharles MA, Duby S, Wadell RW, et al. Limitation of joint mobility (cheiroarthropathy) in adult noninsulin-dependent diabetic patients. Ann Rheum Dis 1984; 43: 251-7
81. Gertner E, Sukenik S, Gladman DD. HLA antigens and nailfold capillary microscopy studies in patients with insulin dependent and noninsulin dependent diabetes mellitus and limited joint mobility. J Rheumatol 1990; 17: 1375-9
82. Brik R, Berant M, Vardi P. The scleroderma-like syndrome of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1991; 7: 121-8
83. Rosenbloom AL, Silverstein JH, Lezotte DC, et al. Limited joint mobility in childhood diabetes mellitus indicates risk for microvascular disease. N Engl J Med 1981; 305: 191-4
84. Cohn BA, Wheeler CE, Briggamon RA. Scleredema adultorum of Buschke and diabetes mellitus. Arch Dermatol 1970; 101: 27-35
85. Cole GW, Headley J, Skowsky R. Scleredema diabeticorum: a common and distinct cutaneous manifestation of diabetes mellitus. Diabetes Care 1983; 6: 189-92
86. Venencie PY, Powell FC, Su WP, et al. Scleredema: a review of thirty-three cases. J Am Acad Dermatol 1984; 11 (1): 128-34
87. Kunzelmann V, Schnelle C, Audring H, et al. Scleredema diabeticorum: report of 4 cases. Hautarzt 1996; 47: 214-7
88. Ikeda Y, Suehiro T, Abe T, et al. Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin E1. Intern Med 1998; 37: 861-4
89. Sattar MA, Diab S, Sugathan TN, et al. Scleroderma diabeticorum: a minor but often unrecognized complication of diabetes mellitus. Diabet Med 1988; 5: 465-8
90. Lieberman LS, Rosenbloom AL, Riley WJ, et al. Reduced skin thickness with pump administration of insulin [letter]. N Eng J Med 1980; 303: 940-1
91. McFadden N, Ree K, Soyland E, et al. Scleredema adultorum associated with a monoclonal gammopathy and generalized hyperpigmentation. Arch Dermatol 1987; 123: 629-32
92. Valente L, Velho GC, Farinha F, et al. Scleredema, acanthosis nigricans and IgA/Kappa multiple myeloma. Ann Dermatol Venereol 1997; 124: 537-9
93. Konohana A, Kawakubo Y, Tajima S, et al. Glycosaminoglycans and collagen in skin of a patient with diabetic scleredema. Keio J Med 1985; 34: 221-6
94. Varga J, Gotta S, Li L, et al. Scleredema adultorum: case report and demonstration of abnormal expression of extracellular matrix genes in skin fibroblasts in vivo and in vitro. Br J Dermatol 1995; 132: 992-9
95. Sibbald RG, Landolt SJ, Toth D. Skin and diabetes. Endocrinol Metab Clin North Am 1996; 25: 463-72
96. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-48
97. Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol 1994; 31: 1-19
98. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med 1995; 99: 420-6
99. Stoddart ML, Blevins KS, Lee ET, et al. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. Diabetes Care 2002; 25: 1009-14
100. Mukhtar Q, Cleverley G, Voorhees RE, et al. Prevalence of acanthosis nigricans and its association with hyperinsulinemia in New Mexico adolescents. J Adolesc Health 2001; 28: 372-6
101. Nguyen TT, Keil MF, Russell DL, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children. J Pediatr 2001; 138: 453-4
102. Stuart CA, Driscoll MS, Lundquist KF, et al. Acanthosis nigricans. J Basic Clin Physiol Pharmacol 1998; 9: 407-18
103. Burke JP, Hale DE, Hazuda HP, et al. A quantitative scale of acanthosis nigricans. Diabetes Care 1999; 22: 1655-9
104. Huntley A. Photoessay: the skin and diabetes mellitus diabetes and thick skin. Dermatol Online J 1995 Dec; 1 (2)
105. Cruz PD, Hud JA. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98 (6 Suppl.): 82S-5S
106. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol 2002; 147: 1096-101
107. Akiyama M, Sawamura D, Shimizu H. The clinical spectrum of nonbullous congenital ichthyosiform erythroderma and lamellar ichthyosis. Clin Exp Dermatol 2003; 28: 235-40
108. Okulicz JF, Schwartz RA. Hereditary and acquired ichthyosis vulgaris. Int J Dermatol 2003; 42: 95-8
109. Smith F. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003; 4: 347-64
110. DiGiovanna JJ, Robinson-Bostom L. Ichthyosis: etiology, diagnosis, and management. Am J Clin Dermatol 2003; 4: 81-95
111. Meurer M. Szeimies RM. Diabetes mellitus and skin diseases. Curr Probl Dermatol 1991; 20: 11-23
112. Braverman IM. Skin signs of systemic disease. Philadelphia (PA): WB Saunders, 1981: 654-664
113. Muller SA, Winkelmann RK. Necrobiosis lipoidica diabeticorum. Arch Dermatol 1966; 93: 272-81
114. De Silva BD, Schofield OM, Walker JD. The prevalence of necrobiosis lipoidica diabeticorum in children with type 1 diabetes. Br J Dermatol 1999; 141: 593-4
115. Heng MC, Allen SG, Song MK, et al. Focal endothelial cell degeneration and proliferative endarteritis in trauma-induced early lesions of necrobiosis lipoidica diabeticorum. Am J Dermatopathol 1991; 13: 108-14
116. Verrotti A, Chiarelli F, Amerio P, et al. Necrobiosis lipoidica diabeticorum in children and adolescents: a clue for underlying renal and retinal disease. Pediatr Dermatol 1995; 12: 220-3
117. Kelly WF, Nicholas J, Adams J, et al. Necrobiosis lipoidica diabeticorum: association with background retinopathy, smoking, and proteinuria: a case controlled study. Diabet Med 1993; 10: 725-8
118. Bouhanick B, Verret JL, Gouello JP, et al. Necrobiosis lipoidica: treatment by hyperbaric oxygen and local corticosteroids. Diabetes Metab 1998; 24: 156-9
119. Weisz G, Ramon Y, Waisman D, et al. Treatment of necrobiosis lipoidica diabeticorum by hyperbaric oxygen. Acta Derm Venereol 1993; 73: 447-8
120. Quimby SR, Muller SA, Schroeter AL. The cutaneous immunopathology of necrobiosis lipoidica. Arch Dermatol 1988; 124: 1364-71
121. Magro CM, Crowson AN, Regauer S. Granuloma annulare and necrobiosis lipoidica tissue reactions as a manifestation of systemic disease. Hum Pathol 1996; 27: 50-6
122. Carter VH, Constantine VS. Kyrle's disease. Arch Dermatol 1968; 97: 624-39
123. Poliak SC, Lebwohl MG, Parris A, et al. Reactive perforating collagenosis associated with diabetes mellitus. N Engl J Med 1982; 306: 81-4
124. Detmar M, Ruszczak Z, Imcke E, et al. Kyrle's disease in juvenile diabetes mellitus and chronic renal failure. Z Hautkr 1990; 65: 53-61
125. Briggs PL, Fraga S. Reactive perforating collagenosis of diabetes mellitus. J Am Acad Dermatol 1995; 32: 521-3
126. Pedragosa R, Knobel HJ, Huguet P, et al. Reactive perforating collagenosis in Hodgkin's disease. Am J Dermatopathol 1987; 9: 41-4
127. Bank DE, Cohen PR, Kohn SR. Reactive perforating collagenosis in a setting of double disaster: acquired immunodeficiency syndrome and end-stage renal disease. J Am Acad Dermatol 1989; 21: 371-4
128. Faver IR, Daoud MS, Su WP. Acquired reactive perforating collagenosis: report of six cases and review of the literature. J Am Acad Dermatol 1994; 30: 575-80
129. Iwamoto I, Baba S, Suzuki H. Acquired reactive perforating collagenosis with IgA nephropathy. J Dermatol 1998; 25: 597-600
130. Chae KS, Park YM, Cho SH, et al. Reactive perforating collagenosis associated with periampullary carcinoma. Br J Dermatol 1998; 139: 548-50
131. Millard PR, Young E, Harrison DE, et al. Reactive perforating collagenosis: light, ultrastructural and immunohistological studies. Histopathology 1986; 10: 1047-56
132. Morgan MB, Truitt CA, Taira J, et al. Fibronectin and the extracellular matrix in the perforating disorders of the skin. Am J Dermatopathol 1998; 20: 1147-54
133. Rapini RP, Herbert AA, Drucker CR. Acquired perforating dermatosis: evidence for combined transepidermal elimination of both collagen and elastic fibers. Arch Dermatol 1989; 125: 1074-8
134. Herzinger T, Schirren CG, Sander CA, et al. Reactive perforating collagenosis: transepidermal elimination of type IV collagen. Clin Exp Dermatol 1996; 21: 279-82
135. Yanagihara M, Fujita T, Shirasaki A, et al. The pathogenesis of the transepithelial elimination of the collagen bundles in acquired reactive perforating collagenosis: a light and electron microscopical study. J Cutan Pathol 1996; 23: 398-403
136. Kawakami T, Saito R. Acquired reactive perforating collagenosis associated with diabetes mellitus: eight cases that meet Faver's criteria. Br J Dermatol 1999; 140: 521-4
137. Kramer DW. Early or warning signs of impending gangrene in diabetes. Med J Rec 1930; 132: 338-42
138. Cantwell AR, Martz W. Idiopathic bullae in diabetics. Bullosis diabeticorum. Arch Dermatol 1967; 96: 42-4
139. Bernstein JE, Medenica M, Soltani K, et al. Bullous eruption of diabetes mellitus. Arch Dermatol 1979; 115: 324-5
140. Rocca F, Pereyra E. Phlyctenar lesions in the feet of diabetic patients. Diabetes 1963; 12: 220-2
141. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes: diabetes in America. 2nd ed. Bethesda (MD): National Diabetes Data Group, National Institutes of Health, 1995. NIH Publication 409-429
142. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992; 152: 610-6
143. Unwin N. Epidemiology of lower extremity amputation in centers in Europe, North America, and East Asia. Br J Surg 2000; 87: 328-37
144. Harrington C, Zagari MJ, Corea J, et al. A cost analysis of diabetic lower extremity ulcers. Diabetes Care 2000; 23: 1333-8
145. Apelqvist J, Ragnarson-Tennvall G, Persson U, et al. Diabetic foot ulcers in a multidisciplinary setting: an economic analysis of primary healing and healing with amputation. J Intern Med 1994; 23: 463-71
146. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998; 21: 296-309
147. Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus. Ann Intern Med 1992; 117: 97-105
148. Caputo GM, Cavanagh PR, Ulbrecht JS, et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994; 331: 854-60
149. Boyko EJ, Ahroni JH, Stensel V, et al. A prospective study of risk factors for diabetic foot ulcer: the Seattle Diabetic Foot Study. Diabetes Care 1999; 22: 1036-42
150. Frykberg RG. Diabetic foot ulcers: current concepts. J Foot Ankle Surg 1998; 37: 440-6
151. Frykberg RG, Armstrong DG, Giurini J, et al. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg 2000; 39 (5 Suppl.): S1-60
152. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-62
153. Boulton AJ. The diabetic foot: a global view. Diabetes Metab Res Rev 2000; 16 Suppl. 1: S2-5
154. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003; 361: 1545-51
155. Swartz MN. Clinical practice: cellulitis. N Engl J Med 2004; 350: 904-12
156. McNeely MJ, Boyko EJ, Ahroni JH, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration: how great are the risks? Diabetes Care 1995; 18: 216-9
157. Flynn MD, Tooke JE. Aetiology of diabetic foot ulceration: a role for the microcirculation? Diabet Med 1992; 9: 320-9
158. Tooke JE, Brash PD. Microvascular aspects of diabetic foot disease. Diabet Med 1996; 13 Suppl. 1: S26-9
159. Akbari CM, LoGerfo FW. Diabetes and peripheral vascular disease. J Vasc Surg 1999; 30: 373-84
160. LoGerfo FW, Coffman JD. Vascular and microvascular disease of the foot in diabetes. N Engl J Med 1984; 311: 1615-9
161. Rendell MS, Milliken BK, Finnegan MF, et al. The skin blood flow response in wound healing. Microvasc Res 1997; 53: 222-34
162. Timar-Banu O, Beauregard H, Tousignant J, et al. Development of noninvasive and quantitative methodologies for the assessment of chronic ulcers and scars in humans. Wound Repair Regen 2001; 9: 123-32
163. Rendell M, Saxena S, Shah D. Cutaneous blood flow and peripheral resistance in type II diabetes as compared to intermittent claudication patients. Int J Angiology 2003; 12: 166-71
164. Nabuurs-Franssen M, Houben A, Tooke J, et al. The effect of polyneuropathy on foot microcirculation in Type II diabetes. Diabetologia 2002; 45: 1164-71
165. Rayman G, Williams SA, Spencer PD, et al. Impaired microvascular hyperaemic response to minor skin trauma in type I diabetes. BMJ 1986; 292: 1295-8
166. Greenhalgh EG. The role of growth factors in wound healing. J Trauma 1996; 41: 59-67
167. Steed DL. The role of growth factors in wound healing. Surg Clin North Am 1997; 77: 575-86
168. Ackerman NB, Brinkley FB. Oxygen tensions in normal and ischemic tissues during Hyperbaric therapy. JAMA 1966; 198: 142-5
169. Hunt TK, Zederfeld B, Goldstick TK. Oxygen and healing. Am J Surg 1969; 118: 521-5
170. Niinikoski J. Effect of oxygen supply on wound healing and formation of experimental granulation tissue. Acta Physiol Scand 1969; 334: 1-72
171. Knighton DR, Silver IA, Hunt TK. Regulation of wound healing angiogenesis: effect of oxygen gradients and inspired oxygen concentration. Surgery 1981; 90: 262-70
172. Heng MC, Harker J, Csathy G, et al. Angiogenesis in necrotic ulcers treated with hyperbaric oxygen. Ostomy Wound Manage 2000; 46 (9): 18-28, 30-2
173. Kalani M, Jorneskog G, Naderi N, et al. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers: long-term follow-up. J Diabetes Complications 2002; 16: 153-8
174. Brakora MJ, Sheffield PJ. Hyperbaric oxygen therapy. Clin Podiatr Med Surg 1995; 12: 105-17
175. Kivisaari J, Niinikoski J. Effects of hyperbaric oxygenation and prolonged hypoxia on the healing of open wounds. Acta Chir Scand 1975; 141: 14-9
176. Boykin JV. Hyperbaric oxygen therapy: a physiological approach to selected problem wound healing. Wounds 1996; 8: 183-98
177. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. Diabetes Care 1996; 19: 1338-43
178. Ciaravino ME, Friedell ML, Kammerlocher TC. Hyperbaric oxygen in treatment of nonhealing wounds. Ann Vasc Surg 1996; 10: 558-62
179. Chantelau E. Hyperbaric oxygen therapy for diabetic foot ulcers. Diabetes Care 1997; 20: 1207-8
180. Bakker DJ. Hyperbaric oxygen therapy and the diabetic foot. Diabetes Metab Res Rev 2000; 16 Suppl. 1: S55-8
181. Cianci P. Adjunctive Hyperbaric oxygen therapy in the treatment of the diabetic foot. J Am Podiatr Med Assoc 1994; 84: 448-55
182. Baroni G, Porro T, Fuglia E, et al. Hyperbaric oxygen in diabetic gangrene treatment. Diabetes Care 1978; 10: 81-6
183. Hart GB, Lamb RC, Strauss MB. Gas gangrene I: a collective review. II. A 15-year experience hyperbaric oxygen. J Trauma 1983; 23: 991-1000
184. Stephens MB. Gas gangrene: potential for hyperbaric oxygen therapy. Postgrad Med 1996; 99: 217-20, 224
185. Hirn M. Hyperbaric oxygen in the treatment of gas gangrene and perineal necrotizing fasciitis. Eur J Surg Suppl 1993; (570): 1-36
186. Baker SR, Stacey MC, Singh G, et al. Aetiology of chronic leg ulcers. Eur J Vasc Surg 1992; 6: 245-51
187. McNeil G, Paduano D. Patients with diabetes and venous stasis ulcers. J Wound Ostomy Continence Nurs 1996; 23: 322-4
188. Fu X, Sheng Z, Cherry GW, et al. Epidemiological study of chronic dermal ulcers in China. Wound Repair Regen 1998; 6: 21-7
189. London NJ, Donnelly R. ABC of arterial and venous disease: ulcerated lower limb. BMJ 2000; 320: 1589-91
190. Nelzen O, Bergqvist D, Lindhagen A. Long-term prognosis for patients with chronic leg ulcers: a prospective cohort study. Eur J Vasc Endovasc Surg 1997; 13: 500-8
191. Malanin K, Havu VK, Kolari PJ. Dynamics of cutaneous laser Doppler flux with concentration of moving blood cells and blood cell velocity in legs with venous ulcers and in healthy legs. Angiology 2004; 55: 37-42
192. Geschwandtner ME, Ehringer H. Microcirculation in chronic venous insufficiency. Vasc Med 2001; 6: 169-79
193. Loots MA, Lamme EN, Zeegelaar J, et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998; 111: 850-7
194. Hahn J, Junger M, Friedrich B, et al. Cutaneous inflammation limited to the region of the ulcer in chronic venous insufficiency. Vasa 1997; 26: 277-81
195. Junger M, Hahn U, Bort S, et al. Significance of cutaneous microangiopathy for the pathogenesis of dermatitis in venous congestion due to chronic venous insufficiency. Wien Med Wochenschr 1994; 144: 206-10
196. Steins A, Hahn M, Junger M. Venous leg ulcers and microcirculation. Clin Hemorheol Microcirc 2001; 24: 147-53
197. Billmann MK, Kohler CH, Varelas X, et al. Konservative befundadaptierte Therapie von superinfizierten chronischen venös bedingten Ulcera cruris. Vasa 2004; 33: 97-101
198. Brem H, Kirsner RS, Falanga V. Protocol for the successful treatment of venous ulcers. Am J Surg 2004; 188 (1A): 1-8
199. Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet 2004; 363 (9424): 1854-9
200. Amann-Vesti BR, Ruesch C, Gitzelmann G, et al. Microangiopathy of split-skin grafts in venous ulcers. Dermatol Surg 2004; 30: 399-402
201. Kaplan RM, Criqui MH, Deneberg JO, et al. Quality of life in patients with chronic venous disease: San Diego population study. J Vasc Surg 2003; 37: 1047-53
202. Bernstein EF. Clinical characteristics of 500 consecutive patients presenting for laser removal of lower extremity spider veins. Dermatol Surg 2001; 27: 31-3
203. Popoff N. The digital vascular system. Arch Pathol 1934; 18: 295-330
204. Rowell L. Reflex control of the cutaneous vasculature. J Invest Dermatol 1959; 69: 154-66
205. Rendell MS, Finnegan MF, Healy JC, et al. The relationship of laser Doppler skin blood flow measurements to the cutaneous microvascular anatomy. Microvasc Res 1998; 55: 3-13
206. Rowell LB. Cardiovascular adjustments to thermal stress. In: Shepherd JT, Abboud FM, editors. Handbook of physiology. Section 2: The Cardiovascular System. Vol 3, pt 2. Bethesda (MD): American Physiological Society, 1983: 967-1023
207. Taylor WF, Johnson JM, O'Leary D, et al. Effect of high local temperature on reflex cutaneous vasodilation. J Appl Physiol 1984; 57: 191-6
208. Brem H, Sheehan P, Boulton AJ. Protocol for treatment of diabetic foot ulcers. Am J Surg 2004 May; 187 (5A): 1S-10S